BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 22496481)

  • 1. Identification and characterization of MEL-3, a novel AR antagonist that suppresses prostate cancer cell growth.
    Helsen C; Marchand A; Chaltin P; Munck S; Voet A; Verstuyf A; Claessens F
    Mol Cancer Ther; 2012 Jun; 11(6):1257-68. PubMed ID: 22496481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
    Hara T; Miyazaki J; Araki H; Yamaoka M; Kanzaki N; Kusaka M; Miyamoto M
    Cancer Res; 2003 Jan; 63(1):149-53. PubMed ID: 12517791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of a novel androgen receptor antagonist, MEL-6, with stereoselective activity and optimization of its metabolic stability.
    Helsen C; Karypidou K; Thomas J; De Leger W; Nguyen T; Joniau S; Voet A; Dehaen W; Claessens F
    J Steroid Biochem Mol Biol; 2024 May; 239():106476. PubMed ID: 38311010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-based virtual screening and identification of a novel androgen receptor antagonist.
    Song CH; Yang SH; Park E; Cho SH; Gong EY; Khadka DB; Cho WJ; Lee K
    J Biol Chem; 2012 Aug; 287(36):30769-80. PubMed ID: 22798067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel steroidal antiandrogen targeting wild type and mutant androgen receptors.
    Andrieu T; Bertolini R; Nichols SE; Setoud R; Frey FJ; Baker ME; Frey BM
    Biochem Pharmacol; 2011 Dec; 82(11):1651-62. PubMed ID: 21907706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The discovery of novel human androgen receptor antagonist chemotypes using a combined pharmacophore screening procedure.
    Voet A; Helsen C; Zhang KY; Claessens F
    ChemMedChem; 2013 Apr; 8(4):644-51. PubMed ID: 23436650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiandrogens prevent stable DNA-binding of the androgen receptor.
    Farla P; Hersmus R; Trapman J; Houtsmuller AB
    J Cell Sci; 2005 Sep; 118(Pt 18):4187-98. PubMed ID: 16141232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-activity relationship of novel (benzoylaminophenoxy)phenol derivatives as anti-prostate cancer agents.
    Kazui Y; Fujii S; Yamada A; Ishigami-Yuasa M; Kagechika H; Tanatani A
    Bioorg Med Chem; 2018 Oct; 26(18):5118-5127. PubMed ID: 30228001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of Androgen-Antagonistic Coumarinamides with a Unique Aromatic Folded Pharmacophore.
    Koga H; Negishi M; Kinoshita M; Fujii S; Mori S; Ishigami-Yuasa M; Kawachi E; Kagechika H; Tanatani A
    Int J Mol Sci; 2020 Aug; 21(15):. PubMed ID: 32759847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells.
    Ishikura N; Kawata H; Nishimoto A; Nakamura R; Tsunenari T; Watanabe M; Tachibana K; Shiraishi T; Yoshino H; Honma A; Emura T; Ohta M; Nakagawa T; Houjo T; Corey E; Vessella RL; Aoki Y; Sato H
    Int J Oncol; 2015 Apr; 46(4):1560-72. PubMed ID: 25634071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen receptor antagonists for prostate cancer therapy.
    Helsen C; Van den Broeck T; Voet A; Prekovic S; Van Poppel H; Joniau S; Claessens F
    Endocr Relat Cancer; 2014 Aug; 21(4):T105-18. PubMed ID: 24639562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iminoenamine based novel androgen receptor antagonist exhibited anti-prostate cancer activity in androgen independent prostate cancer cells through inhibition of AKT pathway.
    Divakar S; Saravanan K; Karthikeyan P; Elancheran R; Kabilan S; Balasubramanian KK; Devi R; Kotoky J; Ramanathan M
    Chem Biol Interact; 2017 Sep; 275():22-34. PubMed ID: 28757136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, Synthesis and Evaluation of Novel Substituted (5-methyl-1H-pyrazol-3-yl)- 1,3,4-oxadiazole as Potent Androgen Receptor Antagonist.
    Andavar S; Vaithilingam M; Selvaraj D; Kumaran AA; Devanathan K
    Anticancer Agents Med Chem; 2020; 20(1):84-93. PubMed ID: 31755396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of novel androgen receptor antagonists using structure- and ligand-based methods.
    Li H; Ren X; Leblanc E; Frewin K; Rennie PS; Cherkasov A
    J Chem Inf Model; 2013 Jan; 53(1):123-30. PubMed ID: 23278403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3 beta-acetoxyandrost-1,5-diene-17-ethylene ketal functions as a potent antiandrogen with marginal agonist activity.
    Miyamoto H; Marwah P; Marwah A; Lardy H; Chang C
    Proc Natl Acad Sci U S A; 2003 Apr; 100(8):4440-4. PubMed ID: 12672951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Learning from estrogen receptor antagonism: structure-based identification of novel antiandrogens effective against multiple clinically relevant androgen receptor mutants.
    Liu B; Geng G; Lin R; Ren C; Wu JH
    Chem Biol Drug Des; 2012 Mar; 79(3):300-12. PubMed ID: 22151347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular mechanism of R-bicalutamide switching from androgen receptor antagonist to agonist induced by amino acid mutations using molecular dynamics simulations and free energy calculation.
    Liu H; Han R; Li J; Liu H; Zheng L
    J Comput Aided Mol Des; 2016 Dec; 30(12):1189-1200. PubMed ID: 27848066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of novel androgen receptor degrading agents to treat advanced prostate cancer.
    Wu H; Ren J; Zhao L; Li Z; Ye W; Yang Y; Wang J; Bian J
    Eur J Med Chem; 2021 May; 217():113376. PubMed ID: 33756125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
    Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
    Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor function.
    Comuzzi B; Lambrinidis L; Rogatsch H; Godoy-Tundidor S; Knezevic N; Krhen I; Marekovic Z; Bartsch G; Klocker H; Hobisch A; Culig Z
    Am J Pathol; 2003 Jan; 162(1):233-41. PubMed ID: 12507906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.